Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Sees Large Decrease in Short Interest

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totaling 146,646 shares, a decline of 37.9% from the March 31st total of 236,224 shares. Approximately 1.1% of the shares of the company are sold short. Based on an average trading volume of 67,187 shares, the short-interest ratio is currently 2.2 days.

Hedge Funds Weigh In On Kairos Pharma

Institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new position in Kairos Pharma in the 3rd quarter valued at about $27,000. XTX Topco Ltd increased its position in Kairos Pharma by 290.8% in the 4th quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock valued at $34,000 after acquiring an additional 36,086 shares during the period. Finally, Two Sigma Investments LP acquired a new position in Kairos Pharma in the 3rd quarter valued at about $54,000.

Kairos Pharma Stock Down 1.5%

KAPA stock traded down $0.01 during trading on Tuesday, hitting $0.59. The company had a trading volume of 78,858 shares, compared to its average volume of 85,028. The firm has a market cap of $12.63 million, a PE ratio of -1.97 and a beta of 1.97. Kairos Pharma has a 1-year low of $0.40 and a 1-year high of $2.11. The firm has a 50-day moving average price of $0.60 and a 200-day moving average price of $0.75.

Kairos Pharma (NYSEAMERICAN:KAPA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that Kairos Pharma will post -0.38 earnings per share for the current year.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical?stage biopharmaceutical company focused on developing small?molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full?length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.